GLP-1 medication shortage tracker

• 0.25 mg/0.5 mL penLimited

  Intermittent regional outages

• 0.5 mg/0.5 mL penLimited
• 1 mg/0.74 mL penAvailable
• 2 mg/1.5 mL penAvailable

Low-dose initiation pens remain the bottleneck. Telehealth providers prioritize already-titrated patients. Most patients escalate to 1 mg+ pens within 90 days, where supply is stable.

• 0.25 mg/0.5 mL penUnavailable

  Starter dose — most affected

• 0.5 mg/0.5 mL penUnavailable
• 1 mg/0.5 mL penLimited
• 1.7 mg/0.75 mL penAvailable
• 2.4 mg/0.75 mL penAvailable

Starter doses (0.25, 0.5 mg) remain on FDA shortage list. New-patient initiation requires patience or pharmacy hopping. Established patients on 1.7/2.4 mg maintenance doses are not impacted.

• 0.25 mg/0.5 mL penLimited

  Intermittent regional outages

• 0.5 mg/0.5 mL penLimited
• 1 mg/0.74 mL penAvailable
• 2 mg/1.5 mL penAvailable

Ozempic shares the same active ingredient (semaglutide) as Wegovy. Low-dose initiation pens remain limited; maintenance doses (1 mg, 2 mg) are reliably available. Off-label use for weight loss has not eased demand.

• 2.5 mg/0.5 mL penAvailable
• 5 mg/0.5 mL penAvailable
• 7.5 mg/0.5 mL penAvailable
• 10 mg/0.5 mL penAvailable
• 12.5 mg/0.5 mL penAvailable
• 15 mg/0.5 mL penAvailable

FDA officially resolved Mounjaro shortage in October 2024. Compounded tirzepatide is no longer permitted for production. All doses available through standard pharmacy channels.

• 6 mg/mL pen (3 mL multi-dose)Available

Liraglutide (Saxenda) is not currently on the FDA shortage list. Lower demand vs semaglutide/tirzepatide and patent expiration in late 2024 have eased supply.

• 2.5 mg/0.5 mL penAvailable
• 5 mg/0.5 mL penAvailable
• 7.5 mg/0.5 mL penAvailable
• 10 mg/0.5 mL penAvailable
• 12.5 mg/0.5 mL penAvailable
• 15 mg/0.5 mL penAvailable
• Vial — 2.5 mgAvailable

  Self-pay LillyDirect pharmacy

• Vial — 5 mgAvailable

  Self-pay LillyDirect pharmacy

Same tirzepatide active ingredient as Mounjaro. Shortage resolved October 2024. LillyDirect self-pay vials added a second distribution channel and reduced pharmacy-level scarcity.